Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX vs AG with PD-1 and SBRT in LAPC
NCT06494514Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome, oxaliplatin and fluorouracil in pancreatic cancer (PC) (2 arms). Primary endpoint: Median Progression-Free Survival up to 12 months. Started Apr 2024; status: recruiting.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06494514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494514.